Ctrl Worx Watch List › Company

Propanc Biopharma, Inc. (PPCB): material weakness open at least 2,128 days

By Russell Tomoum, Ctrl Worx™. Built from its own SEC filings. How the Clock works.

Propanc Biopharma, Inc. reported ineffective internal control over financial reporting because of a material weakness in 6 filings since Sep 28, 2021. It stated one or more material weaknesses in 17 more SEC filings that gave no conclusion on whether that control is effective. The latest was its 10-K for the period ended Jun 30, 2026.

Checked against SEC EDGAR: Oct 29, 2026 · Entry #10896

Causes the company named

Segregation of duties · 23Entity-level and governance · 23Accounting expertise and resources · 20Financial close and reporting · 18

What the latest filing says

Exchange Act reports was recorded, processed, summarized and reported on a timely basis due to the material weaknesses in financial reporting as discussed below. Management’s Report on Internal Control over Financial Reporting Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Rule 13a-15(f) and 15d-15(f) of the Exchange Act. The design of any system of controls is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions, regardless of how remote. All internal control systems, no matter how well designed, have inherent limitations. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the [...]

From the controls section of the 10-K filed Sep 25, 2026. Read the full filing on SEC EDGAR.

Company response: Propanc Biopharma, Inc. can send a statement or a link to its remediation update to russell@ctrlworx.com. We post it here, unedited and dated.

Filings

Follow PPCB for free

Get an email when Propanc Biopharma, Inc files a 10-K or 10-Q that reports a material weakness, or says its controls are effective again.

Based on public SEC filings. Causes are grouped into standard categories by Ctrl Worx. The filings are the authority. Ctrl Worx is not affiliated with Propanc Biopharma, Inc. or the SEC. Not investment advice. Why you can rely on the Watch List.